This white paper highlights the challenges of emerging and re-emerging infectious diseases such as TB, MSSA/MRSA, and Ebola.  At Q² Solutions, we support infectious disease clinical trials with a variety of tools including:

• Niche and novel assay development 
• DNA & RNA extraction and next-generation sequencing
• Integrated local lab data management services
• Global laboratory network held to rigorous quality standards and biosafety protocols
  
  

Download this white paper and learn how we are applying the latest technologies to provide insights for better management of infectious disease clinical trials. New diagnostics and therapies developed as a result can then be used against target pathogens and their resistant variants for improved safety.

Authors:
Ayaskant Pany, MD, Medical Laboratory Director and Scientific Advisor Tropical Diseases, Central Laboratories South Africa
Sorika van Niekerk, MSc, UP, SA, Senior Director/General Manager, Central Laboratories South Africa
Stephen Mortlock, DSc.
Wayne R. Hogrefe, Ph.D., D (ABMLI), Vice President, Vaccine unit

Complete the form below to access this white paper